Osteoporosis Medical Services in China

Osteoporosis is a systemic skeletal disorder characterized by reduced bone mass and microarchitectural deterioration of bone tissue, leading to increased bone fragility and susceptibility to low-trauma fractures—most commonly at the spine, hip, and distal radius. It is a hallmark condition managed within Rheumatology and Immunology departments due to its strong associations with chronic inflammatory diseases (e.g., rheumatoid arthritis, ankylosing spondylitis), autoimmune dysregulation, and cytokine-mediated bone resorption. Pathogenically, osteoporosis arises from an imbalance between bone formation by osteoblasts and bone resorption by osteoclasts. In postmenopausal women, estrogen deficiency triggers upregulation of RANKL (receptor activator of nuclear factor kappa-Β ligand), accelerating osteoclast differentiation and activity. In older adults and men, age-related declines in testosterone, growth hormone, vitamin D synthesis, and renal activation of calcitriol further impair bone mineralization. Secondary causes—including glucocorticoid therapy (>5 mg prednisone equivalent/day for ≥3 months), hyperthyroidism, diabetes mellitus, chronic kidney disease, and monoclonal gammopathy—account for ~20–30% of cases and require targeted evaluation. Epidemiologically, osteoporosis affects over 90 million people in China alone, with prevalence rising sharply after age 50: approximately 32% of women and 6% of men aged ≥65 meet diagnostic criteria (based on WHO BMD T-score ≤ −2.5). Globally, one in three women and one in five men over 50 will experience an osteoporotic fracture. Key modifiable risk factors include prolonged immobility, smoking, excessive alcohol intake (>3 drinks/day), low calcium/vitamin D intake, high sodium or caffeine consumption, and long-term proton pump inhibitor use. Non-modifiable risks include female sex, advanced age, Caucasian or Asian ethnicity, family history of hip fracture, and early menopause (<45 years). Beyond physical morbidity, osteoporosis profoundly impacts quality of life: vertebral compression fractures cause chronic back pain, height loss, kyphosis, reduced pulmonary function, and impaired mobility; hip fractures correlate with 20–24% 1-year mortality and often precipitate permanent disability or nursing home admission. Psychologically, patients report heightened anxiety about falling, social withdrawal, depression, and diminished self-efficacy. Early diagnosis via dual-energy X-ray absorptiometry (DXA) and proactive risk stratification using tools like FRAX® are essential to guide pharmacologic intervention and lifestyle optimization—including weight-bearing exercise, fall prevention strategies, and nutritional counseling.

Osteoporosis is a systemic skeletal disorder characterized by reduced bone mass and microarchitectural deterioration of bone tissue, leading to increased bone fragility and susceptibility to low-trauma fractures—most commonly at the spine, hip, and distal radius. In the Department of Rheumatology and Immunology, osteoporosis is managed as a chronic, multifactorial condition often intertwined with autoimmune rheumatic diseases (e.g., rheumatoid arthritis, systemic lupus erythematosus), glucocorticoid use, chronic inflammation, and vitamin D metabolism disorders. Comprehensive management requires risk stratification using tools such as FRAX® and dual-energy X-ray absorptiometry (DXA) to assess bone mineral density (BMD) at the lumbar spine and proximal femur.

Conservative treatment forms the cornerstone of osteoporosis management and must be initiated at diagnosis, regardless of pharmacologic intervention. It includes nutritional optimization: daily calcium intake of 1000–1200 mg (preferably from dietary sources such as dairy, leafy greens, and fortified foods; supplementation only if dietary intake is insufficient), and vitamin D3 supplementation of 800–2000 IU/day to maintain serum 25-hydroxyvitamin D levels ≥30 ng/mL. Weight-bearing and muscle-strengthening exercises are essential—evidence supports supervised programs incorporating resistance training, balance drills (e.g., tai chi), and gait retraining to reduce fall risk by up to 30%. Fall prevention strategies include home safety assessments (removing tripping hazards, installing grab bars), vision screening, medication review for sedative or hypotensive agents, and podiatric evaluation for footwear and orthotics. Smoking cessation and alcohol moderation (<2 standard drinks/day for men, <1 for women) are strongly advised, given their direct negative effects on osteoblast activity and bone turnover.

Pharmacologic therapy is indicated for patients with a prior fragility fracture, T-score ≤ −2.5 at the lumbar spine, femoral neck, total hip, or 33% radius; or those with osteopenia (T-score between −1.0 and −2.5) plus a 10-year major osteoporotic fracture probability ≥20% or hip fracture probability ≥3% per FRAX®. First-line agents include oral bisphosphonates (alendronate, risedronate, ibandronate), which inhibit osteoclast-mediated bone resorption. Intravenous zoledronic acid (5 mg annually) is preferred in patients with gastrointestinal intolerance or poor adherence. Denosumab—a monoclonal antibody targeting RANKL—is administered subcutaneously every six months and demonstrates superior BMD gains and fracture reduction versus oral bisphosphonates, particularly in high-risk populations including glucocorticoid-induced osteoporosis. Anabolic agents are reserved for severe cases: teriparatide (PTH 1–34) and abaloparatide stimulate osteoblast activity and are approved for 18–24 months’ use, followed by an antiresorptive agent to preserve gains. Romosozumab—a sclerostin inhibitor—offers dual action (anabolic followed by antiresorptive effect) and is indicated for postmenopausal women at very high fracture risk; it is administered monthly via subcutaneous injection for 12 months. Selective estrogen receptor modulators (raloxifene) and hormone therapy may be considered in early postmenopausal women with vasomotor symptoms, though cardiovascular and thromboembolic risks require careful individualization.

Surgical treatment is not curative for osteoporosis itself but addresses its most devastating complication: vertebral compression fractures (VCFs). Percutaneous vertebroplasty and kyphoplasty are minimally invasive procedures performed under fluoroscopic guidance. Kyphoplasty—preferred in acute VCFs (<6–8 weeks)—uses inflatable bone tamps to restore vertebral height and create a cavity for polymethylmethacrylate (PMMA) cement, thereby reducing pain, improving sagittal alignment, and lowering adjacent-level fracture risk compared to vertebroplasty. Surgery is indicated for persistent, disabling pain unresponsive to ≥6 weeks of conservative care, progressive deformity, or neurologic compromise. Hip fractures necessitate urgent orthopedic surgical fixation (e.g., intramedullary nailing, hemiarthroplasty) or arthroplasty, followed by immediate initiation of osteoporosis-specific medical therapy to prevent subsequent fractures. Multidisciplinary perioperative protocols—including early mobilization, thromboprophylaxis, and rapid transition to bone-active agents within 2 weeks post-op—are critical to outcomes.

China offers distinct advantages in osteoporosis care, rooted in integrated traditional and modern medicine frameworks. The National Health Commission’s Osteoporosis Prevention and Treatment Guidelines (2022) emphasize standardized DXA access across tertiary hospitals and growing availability in county-level centers. China leads globally in real-world implementation of denosumab and romosozumab, with robust pharmacovigilance systems tracking long-term safety. Traditional Chinese Medicine (TCM) adjuncts—such as Bushen Zhuanggu decoction or Xian Ling Gu Bao capsules—are widely used under rheumatology supervision and supported by randomized trials demonstrating synergistic effects on BMD and bone turnover markers when combined with conventional therapy. Moreover, China’s digital health infrastructure enables AI-assisted fracture risk prediction via mobile apps linked to electronic health records, facilitating proactive community-based screening in aging populations. Cost-effectiveness is enhanced through national drug price negotiations: generic bisphosphonates and denosumab are subsidized under the Essential Drug List, improving adherence in rural and underserved regions.

Recovery and long-term maintenance demand structured follow-up. BMD should be reassessed every 1–2 years during active treatment, with bone turnover markers (e.g., serum P1NP, CTX) monitored every 3–6 months to assess adherence and biological response. Patients must understand that osteoporosis is not cured but controlled—therapy duration is typically ≥5 years for antiresorptives, with drug holidays considered only after thorough re-evaluation in low-risk individuals. Annual clinical assessment includes fall risk reassessment, functional mobility testing (Timed Up-and-Go), and screening for secondary causes (e.g., hyperparathyroidism, multiple myeloma, celiac disease). Psychosocial support is integral: depression and fear of falling significantly impair rehabilitation; cognitive-behavioral interventions and peer-led support groups improve self-efficacy and adherence. Finally, patient education must emphasize that fracture prevention—not just BMD improvement—is the primary therapeutic goal; even modest reductions in fracture incidence translate into substantial gains in quality-adjusted life years, especially among older adults with comorbid rheumatic disease.